# Hope S. Rugo

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/hope-s-rugo/

## Facts

| Field | Value |
| --- | --- |
| Citations | 103,717 |
| Field | Advanced Breast Cancer Therapies |
| h-index | 141 |
| i10-index | 616 |
| Last Known Institution | City Of Hope National Medical Center |
| OpenAlex ID | https://openalex.org/A5090188675 |
| ORCID iD | https://orcid.org/0000-0001-6710-4814 |
| Works | 1,625 |

## Researcher papers

Showing 12 of 25.

- [Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer](https://scholariq.org/papers/trastuzumab-deruxtecan-in-previously-treated-her2-low-advanced-breast-cancer/)
- [Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation](https://scholariq.org/papers/talazoparib-in-patients-with-advanced-breast-cancer-and-a-germline-i-brca-i/)
- [3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)](https://scholariq.org/papers/3rd-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-3/)
- [Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/breast-cancer-version-3-2020-nccn-clinical-practice-guidelines-in-oncology/)
- [Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer](https://scholariq.org/papers/sacituzumab-govitecan-in-metastatic-triple-negative-breast-cancer/)
- [ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer](https://scholariq.org/papers/esmo-clinical-practice-guideline-for-the-diagnosis-staging-and-treatment-of/)
- [5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)](https://scholariq.org/papers/5th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-5/)
- [Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/effect-of-interleukin-1-inhibition-with-canakinumab-on-incident-lung-cancer-in/)
- [Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer](https://scholariq.org/papers/randomized-phase-iii-trial-of-capecitabine-compared-with-bevacizumab-plus/)
- [Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual](https://scholariq.org/papers/breast-cancer-major-changes-in-the-american-joint-committee-on-cancer-eighth/)
- [Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/breast-cancer-version-3-2022-nccn-clinical-practice-guidelines-in-oncology/)
- [Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer](https://scholariq.org/papers/sacituzumab-govitecan-hziy-in-refractory-metastatic-triple-negative-breast/)

## Researcher topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [City Of Hope National Medical Center](https://scholariq.org/institutions/city-of-hope-national-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.